CStone Pharmaceuticals (HKG:2616) booked a loss of 437 million yuan in 2025, widening from 91.2 million yuan a year earlier, according to a Thursday Hong Kong bourse filing.
Shares of the pharmaceutical firm were up nearly 18% in late Friday morning trade.
Loss per share came in at 0.31 yuan, compared with 0.07 yuan a year earlier.
Revenue fell 34% to 269.6 million yuan from 407.2 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments